All-trans retinoic acid in combination with α-interferon and dexamethasone for advanced multiple myeloma

Pellegrino Musto, Maria Rosaria Sajeva, Grazia Sanpaolo, Giovanni D'Arena, Potito Rosario Scalzulli, Mario Carotenuto

Research output: Contribution to journalArticlepeer-review

Abstract

The in vitro inhibitory effect of all-trans retinoic acid (ATRA) on myeloma cell growth may be synergistically potentiated by the activity of dexamethasone (DEX) and α-interferon (IFN). We treated 10 patients with advanced, refractory multiple myeloma (MM) using a combination of ATRA (100 mg p.o., once a day for two weeks every month), DEX (40 mg i.v., for 4 days every 4 weeks) and IFN (3 MU s.c., three times a week). Eight patients completed at least three months of treatment and were evaluable for response. Two of them showed a partial response which persists after 15 to 17 months. Three patients experienced a stable plateau phase of 4 to +11 months, with a significant improvement in the performance status and bone pain. Progressive disease was seen in the remaining three patients. We conclude that the association of ATRA, DEX and IFN warrants further consideration in MM patients.

Original languageEnglish
Pages (from-to)354-356
Number of pages3
JournalHaematologica
Volume82
Issue number3
Publication statusPublished - May 1997

Keywords

  • All-trans retinoic acid
  • Dexamethasone
  • Interferon
  • Interleukin-6
  • Multiple myeloma

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'All-trans retinoic acid in combination with α-interferon and dexamethasone for advanced multiple myeloma'. Together they form a unique fingerprint.

Cite this